Ivabradine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Ivabradine

Examples of brand names: Procoralan [EU/DE]

ATC code: C01EB17

Main use (for orientation): Heart failure; angina

Documented research summary

No sufficiently attributable cannabinoid–ivabradine pair is substantiated within the documented search scope. The structured assessment distinguishes supported drug context from missing specific interaction evidence. Missing data do not establish safety.

Uncertainties and limitations

No numerical CBD or THC prediction; consider active metabolites and the administration context. Do not infer independent changes to prescribed medicines from this research dataset.

Structured assessment

Category: Drug context

Cannabinoid scope: No specifically substantiated pair involving a registered cannabinoid in the material assessed; no claim that all 28 cannabinoids were comprehensively reviewed simultaneously.

Evidence status: Drug properties supported by product information; insufficient evidence for a specific cannabinoid–drug pair effect.

Mechanism / drug context: CYP3A4 and an active N-desmethyl metabolite; heart-rate-lowering effect.

Type of supporting material: Product information and documented individual literature screening; no clinical pair trial approved for use as evidence.

Clinical interpretation: Additional bradycardia or a change in exposure has not been quantified for cannabinoids.

Context: Product information describes known interaction pathways involving other substances.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [CA_L_D0205]: Original product information: drug context, not evidence for a cannabinoid–drug pair

Statement supported: CYP3A4 and an active N-desmethyl metabolite; heart-rate-lowering effect.

Source: CORLANOR (IVABRADINE) TABLET, FILM COATED CORLANOR (IVABRADINE) SOLUTION [AMGEN INC] [CA_L_D0205]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: All individual review fields read. Original product information rechecked only in the relevant pharmacokinetic / interaction excerpts; not a complete recertification of all labels or a worldwide full-text search. Literature access through the pre-existing documented screening; only the listed web sources were additionally read in this round. No numerical CBD or THC prediction; consider active metabolites and the administration context.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[CA_L_D0205] CORLANOR (IVABRADINE) TABLET, FILM COATED CORLANOR (IVABRADINE) SOLUTION [AMGEN INC]

Original source / bibliographic reference

Authors: Amgen Inc

Year: 2025

Source type: Official human-use SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility